Streetbeat News

Price Targets

WBA

Deutsche Bank analyst George Hill has downgraded Walgreens Boots Alliance (NASDAQ:WBA) from Buy to Hold and lowered the price target from $46 to $34.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:33 am

REGN

Canaccord Genuity analyst John Newman has downgraded Regeneron Pharmaceuticals from Buy to Hold and lowered the price target from $953 to $720.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:32 am

VEEV

Morgan Stanley analyst Craig Hettenbach has downgraded Veeva Systems (VEEV) from Equal-Weight to Underweight and set a price target of $181.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:30 am

UBER

Daiwa Capital analyst Jairam Nathan has downgraded Uber Technologies from Buy to Outperform and raised the price target from $42 to $51.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:28 am

WMS

Morgan Stanley analyst Joshua Pokrzywinski has downgraded Advanced Drainage Systems (NYSE:WMS) from Overweight to Equal-Weight, while raising the price target from $107 to $114.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:25 am

ANVS

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Annovis Bio (NYSE:ANVS) and maintained a $40 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:16 am

ACIU

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on AC Immune (NASDAQ:ACIU) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:16 am

ZI

Needham has reiterated its 'Buy' rating on ZoomInfo Technologies (NASDAQ:ZI) and maintained its price target of $35.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:15 am

RGLS

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a $9 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:14 am

RZLT

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Rezolute (NASDAQ:RZLT) and maintained a $14 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:14 am